Localized Prostate Cancer Incidence Declines, Distant Stage Rises
Although fewer men are being diagnosed with localized prostate cancer, more are being diagnosed with distant-stage disease.
Prostate Cancer
Fluciclovine PET/CT Improves Prostate Cancer Salvage Radiation Outcomes
Fluciclovine PET/CT plus conventional imaging vs conventional imaging alone to guide radiation therapy for men with recurrent PCa following radical prostatectomy results in improved failure-free survival, according to the first randomized trial comparing the 2 approaches.
Black Men Have Better Outcomes From Radiation-Based Tx for High-Risk PCa
Black race is associated with improved oncologic outcomes among men undergoing radiation-based therapy for high-risk prostate cancer, new findings suggest.
Circulating Tumor Cells May Predict Response to Radium-223 in mCRPC
Pretreatment counts of 5 CTCs per 7.5 mL of blood or higher correlated with shorter survival compared with lower counts among men with metastatic castration-resistant prostate cancer treated with radium-223, a study found.
Understanding the Stigma Experienced by Patients With Prostate Cancer
Interview study reveals men’s perception and concerns related to their prostate cancer journey.
Reliability of Laboratory-Developed Tests Called Into Question
A recent HHS announcement spurred concern that FDA oversight of LDTs was eroding, threatening patient safety — but the reality is less dire.
Immunotherapy in mCRPC: Teasing Out the Right Dosing Schedule
The phase 2 Clinical Trial CheckMate 650 shows promise for some immunotherapy in subset of patients with advanced prostate cancer, but the toxicities are concerning.
Radiation for Abdominal, Pelvic Cancers Ups Secondary Sarcoma Risk
Compared with patients who undergo surgery alone for abdominal or pelvic cancers, those who receive radiation and chemotherapy are at elevated risk for secondary sarcomas.
Black Men With Prostate Cancer Found to Be Reluctant to Participate in Trials
Efforts should be made to address patient concerns about clinical trial participation.
Greater Subcutaneous Fat Improves mCRPC Treatment Response
In a study of men with mCRPC receiving chemotherapy and maximal androgen ablation, those who had an objective response to treatment had a significantly higher subcutaneous adipose tissue index than those who did not.
-
Loading...
-
Loading...
Next post in Prostate Cancer
